Emmanuel Israel Edache; Adamu Uzairu; Paul Andrew Mamza; Gideon Adamu Shallangwa
Abstract
The appearance of severe acute respiratory syndrome coronavirus 2 (COVID-19) is at its peak; with the growing number of people infected with COVID-19, there is an urgent need to find ...
Read More
The appearance of severe acute respiratory syndrome coronavirus 2 (COVID-19) is at its peak; with the growing number of people infected with COVID-19, there is an urgent need to find effective treatments for this outbreak. The current situation appears to call for drug repurposing. In our hunt for a viable medication against this virus, we used an in-silico strategy to test four conventional medicines, including Ritonavir and Hydroxychloroquine, against the spike glycoprotein of COVID-19. A docking simulation was performed to assess the drug's binding affinity. We discovered a single medication compound 36 against SARS-coronavirus spike glycoprotein. The compound was found to have a strong binding affinity against the target protein. The chemical was discovered to have a high affinity for the target protein. Furthermore, no conventional medicines efficiently bonded to the SARS-coronavirus spike glycoprotein. The current investigation concluded that the compound 36 is a highly stable anti-SARS-coronavirus spike glycoprotein medication. Furthermore, none of the standard drugs had a high affinity for the SARS-coronavirus spike glycoprotein binding site.
![(S)-N-(4-Carbamoylphenyl)-8-Cyclopropyl-7-(Naphthalen-1-ylmethyl)-5-Oxo-2,3-Dihydro-5H-Thiazolo[3,2-a]Pyridine-3-Carboxamide, A Better Inhibitor of SARS-Cov-2 Spike Glycoprotein Than Some Standard Drugs: A Computational Prediction](data/ajcsa/coversheet/21668447927.jpg)